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1. Introduction
A new system based on the phenotypic expression of antibiotic resistance has been developed.
The system, the Defined Substrate Utilization® (DSU®) process, enhances the metabolism of
the target microbe while providing inadequate nutrients for the non-target microbes. Accord‐
ingly, the target microbe multiples to a much greater extent than the non-target microbes and
this differential allows for the specific detection of the target microbe. The non-target microbes
multiply insufficiently to be noticed. Incorporated in the DSU® screening tools are substrates,
that when metabolized, produces a sensible signal such as color or luminescence. In addition,
specific inhibitors to the non-target microbes are included in the formulas. This format allows
a more sensitive screen than parallel agar-based methods. In terms of time to positive, the
liquid (once the powder is hydrated with sterile water), coupled with the optimization of
nutrients generates results in the same time frame as genetic amplification tests. The mixing
of the ingredients in powder form permits a much less expensive individual screen than either
conventional agar-based or genetic amplification methods. In addition, the format permits
utilization of the DSU® tools both in the remote field environment or the clinical microbiology
laboratory.
There are two basic protocols utilized for the epidemiological screening of microbes. The first
is the conventional agar-based culture technique. Here a specimen is plated on one or more
selective agars and incubated 24 to 48 hours. A trained medical technologist examines the
colonies and those compatible with the target microbe are subjected to specific biochemical
and/or immunochemical testing, and antibiotic susceptibility procedures. These may require
from 24 to 72 hours incubation [1]. In an attempt to facilitate the culture protocol, chromogenic
substrate media have been introduced for some, but not all, bacteria of epidemiological
interest. Chromogenic substrate agars have a short shelf life, must be stored cold and often in
© 2015 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution,
and reproduction in any medium, provided the original work is properly cited.
the dark, and the colors differentiating the positive and negative colonies may not always be
distinct, necessitating confirmatory testing [2]. They are generally held 48 hours before calling
a negative, although 48 hours can result in false-positives [3, 4].
The second technique utilizes genetic amplification (GA) to detect the target microbe. A
number of companies make different types of GA. However, in common to them all are: each
requires an expensive instrument, utilizes reagents which are expensive, requires highly
skilled labor in a centralized laboratory, and does not recover living bacteria [5]. In addition,
each is subject to false-positives and false-negatives because of unexpected mutations [6, 7].
A new and novel, one-step, direct epidemiology screening method based on classical pheno‐
typic parameters was developed as an alternative to conventional agar-based methods for a
variety of antibiotic resistant bacteria. For example, for Staphylococcus aureus (S. aureus), the
key enzyme is coagulase and specificity is achieved equal to that of conventional identification
schemes [8]. The method of Defined Substrate Utilization® (DSU®) optimizes specific, selective,
and differential biochemicals in powder form. Hence, it overcomes the observation by Selepak
and Witebsky that the lot-to-lot variation of commercial plasma was too variable to be used
directly from patient specimens [9]. For each target microbe, an optimum background of
nutrients and inhibitors was generated tailored to the biochemical physiology of that bacteri‐
um. Accordingly, the target microbes are preferentially fed while the non-target microbes are
in a nutrient deficit.
The powder format allows optimization of ingredients much more precisely than an agar gel.
Moreover, the overall sensitivity of the DSU® method is enhanced since liquid culture (once
the powder is hydrated with sterile water) detects a lower number of colony forming units
(CFU) than on the surface of agar [10, 11]. The DSU® tools are generally positive from a colony
within 4 to 5 hours and from a human or animal sample in 6-9 hours on average. The bacteria
remain viable in the screens and thus provide the opportunity to further evaluate the target
microbe.
In addition to be able to be done manually by visual observation, an inexpensive instrument
was developed to read and analyze results of all the screens (Pilots Point Monitor 60®, Pilots
Point LLC, Sarasota, FL). One may add any combination of any of the DSU® screening tools
into the instrument and results are generated by an algorithm controlling the analysis. Results
can be sent to cell phones, via Wi-Fi, or in any format to any location. For example, the
instruments may be stationed at various clinics.
This paper shall describe in detail four of the epidemiological screens: methicillin-resistant S.
aureus (MRSA), all S. aureus including MRSA and methicillin-susceptible S. aureus (MSSA),
vancomycin-resistant enterococci (VRE), and carbapenemase-resistant Enterobacteriaceae
(CRE). Screens for vancomycin-intermediate resistant S. aureus (VISA), and ciprofloxacin-
resistant (cipR) bacteria will be described briefly as subsets of the above. In addition, the
principles and function of the instrument will be presented.
While this paper presents six of the DSU® epidemiology screens, the format and phenotypic
expression in the presence of defined nutrients, allows for the rapid development of others.
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2. The Defined Substrate Utilization® Method
2.1. Screening Method for S. aureus: Both Methicillin-susceptible (MSSA) and Methicillin-
resistant (MRSA)
2.1.1. EPI-M® and aureusAlert® — Quantitative analysis with pure and anterior nares cultures
[EPI-M® is the DSU® epidemiology screen for MRSA, aureusAlert® is the DSU® epidemiology
screen for all S. aureus – both MSSA and MRSA (Pilots Point LLC, Sarasota, FL)]
2.1.1.1. Pure cultures
S. aureus ATCC 43300 (MRSA), S. aureus ATCC 34591 (MRSA), S. aureus ATCC 25923 (MSSA),
S. aureus ATCC 29213 (MSSA), S. epidermidis ATCC 12228, the MRSA USA 600 (6 isolates),
MRSA USA 300 (2 isolates), and MRSA USA 100 (2 isolates), plus 5 clinical patient laboratory
isolates of MRSA and 5 of MSSA were utilized.
A suspension of each of the bacterial isolates was made in normal physiological saline to a 0.5
McFarland standard. From this suspension, 0.1 mL was transferred to 9.9 mL of sterile normal
saline and vortexed well. Using a quantitative pipette (Rainin, Rainin Instrument LLC,
Oakland, CA) 1 and 10 microliters of the suspension was transferred to aureusAlert® and EPI-
M® and a dilution series generated. Colony counts were made from the 0.5 McFarland standard
and the 9.9 mL normal saline [8].
2.1.1.2. Human surveillance study
Nasal swabs (Culturette™ II, Becton, Dickinson and Company, Cockeysville, MD) were
obtained from people entering or leaving a building at the following locations: Yale-New
Haven Hospital (New Haven, CT, USA); Walter E. Washington Convention Center (Wash‐
ington, D.C., DC, USA), George Washington University Hospital (Washington, D.C., DC, USA)
and Tampa General Hospital (Tampa, FL, USA). Two swabs were obtained from the same
nostril.
2.1.1.3. Conventional procedure
S. aureus: Volunteer nasal swab specimens were aseptically transferred to Trypticase Soy Broth
(TSB) containing 6.5% NaCl for 24 hours enrichment at 33°C-35ºC. The enrichment samples
were subcultured on to Tryptic Soy Sheep Blood Agar (TSBA) plates, and the plates were
incubated aerobically for 24 hours at 35°C. Suspicious colonies of S. aureus were identified by
using standard laboratory methods including catalase, tube or slide coagulase, Gram staining,
and mannitol salt agar. Confirmed S. aureus colonies were tested for methicillin resistance
using the CLSI recommended reference method (e.g., 30 mcg cefoxitin disk) [12]. In addition,
an assay for PBP-2 (Remel, Lenexa, KS) was performed.
MRSA: Cultures were inoculated into TSB with 6.5% NaCl and incubated for 18-24 hours. A
subculture was made to blood agar (BA) plates and a Staphaurex® (Remel, Lenexa, KS) test
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performed. In addition, an assay for PBP-2 (Remel, Lenexa, KS) was performed. Antibiotic
susceptibility test (AST) was performed by both an agar dilution method (Mueller-Hinton agar
with 4 mcg/mL oxacillin, Becton, Dickinson and Company, Cockeysville, MD) and also by the
Sensititre™ (Trek Diagnostic Systems, Oakwood Village, OH) microdilution method.
2.1.1.4. Defined Substrate Utilization® screens
All ingredients of the Defined Substrate Utilization® screens are optimized in powder form in
a tube and are performed in the same way. Each tube is labelled with the name of the screen,
and a specific amount of water is transferred to the tube to hydrate the powder. The sample
is added to the tube and incubated at 35°C. A positive result, which can occur any time after
the initiation of incubation, is seen as follows:
Interpretation: aureusAlert® – a clot or coalescence forms in the liquid; no observable clot or
coalescence is a negative result. EPI-M® – the liquid changes color from straw-colored to
amethyst with an increase in coalescence; no change from straw-colored is a negative result.
Tubes are held a maximum of 24 hours before calling them negative.
Control S. aureus standards ATCC 25923 (MSSA) and ATCC 43300 (MRSA) plus 5 MSSA and
5 MRSA isolates from patients were tested. MSSA and MRSA isolates were diluted from 7
log10 to 1 log10 and incubated at 35° and 23°C.
Based on quantitative analysis of pure cultures, the Defined Substrate Utilization® screens were
able to detect as low as 20 CFU (18 hours of incubation) with both MSSA and MRSA (Table 1;
Table 3). Tables 2A and 2B, and Tables 4A and 4B, present the results of the nasal screening of
normal subject volunteers. For both the detection of S. aureus and MRSA there was no
difference between the Defined Substrate Utilization® screens and conventional methods.
aureusAlert® and EPI-M® showed a specificity of 100%.
2.1.2. aureusAlert® for all S. aureus (MSSA & MRSA)
Figure 1. S. aureus Negative – Liquid
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Figure 2. S. aureus Positive – Clot
MSSA ATCC 25923 (CFU/mL) Detection Time at 35°C
7 log10 2.0 h
6 log10 3.0 h
5 log10 4.0 h
4 log10 7.0 h
3 log10 10.0 h
2 log10 15.0 h
Table 1. Detection time of Quality Control Clone ATCC 25923 in aureusAlert®
Conventional Positive Conventional Negative Total
aureusAlert® Positive 450 20 470
aureusAlert® Negative 10 1787 1797
Total 460 1807 2267
(A)
Site aureusAlert
®
(Positive / Negative)
Conventional
(Positive / Negative)
Tampa General Hospital 69 / 322 72 / 322
Yale-New Haven Hospital 63 / 289 58 / 289
(B)
Table 2. A&B. Detection comparison of S. aureus nasal swabs in aureusAlert® and conventional methods
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2.1.3. EPI-M® (MRSA)
Figure 3. MRSA Negative – Straw-colored
Figure 4. MRSA Positive – Amethyst
MRSA ATCC 43300 (CFU/mL) Detection Time at 35°C
7 log10 2.0 h
6 log10 3.0 h
5 log10 4.0 h
4 log10 6.5 h
3 log10 14.0 h
2 log10 18.0 h
Table 3. Detection time of Quality Control Clone ATCC 43300 in EPI-M®
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Conventional Positive Conventional Negative Total
EPI-M® Positive 49 2 51
EPI-M® Negative 1 480 481
Total 50 482 532
(A)
Site EPI-M®(Positive / Negative)
Conventional
(Positive / Negative)
Tampa General Hospital 33 / 317 32 / 317
Yale-New Haven Hospital 19 / 217 18 / 217
(B)
Table 4. A & B. Detection comparison of MRSA nasal swabs in EPI-M® and conventional methods
Described here is a method to detect S. aureus, both MSSA and MRSA, directly from a human,
animal, or environmental sample. The key innovation was to optimize all ingredients and
generate a stable, ready-to-use powder. The system’s central ingredient is an enhanced
coagulase substrate. The enhanced coagulase reaction overcame the observation by Selepak
and Witebsky that rabbit plasma variability precluded the ability to directly detect S. aureus
directly from samples. In one form, aureusAlert®, all S. aureus are detected. Using the
aureusAlert® as a base, the addition of a mecA inducer specifically distinguishes MRSA (EPI-
M®). By employing the definitive tests in the right milieu, as low as 20 CFU of MSSA and MRSA
could be detected.
This study demonstrated that the sensitivity was equivalent to conventional methods by direct
comparison and molecular methods from literature references. The time to detection was in
the clinically useful range for the epidemiological screening of anterior nares (Table 1; Table
3). Because coagulase was chosen as the core detection system, a specificity of 49/49 for EPI-
M® was seen from sampled subjects. Likewise, aureusAlert® being an enhanced coagulase test
also showed complete agreement with conventional identifications.
The bacteria remain viable in the aureusAlert® and EPI-M® epidemiology screening tools. The
tubes can be transported, as is, from the field for further analysis (e.g., antibiotic susceptibility
testing, molecular fingerprinting). The powder format offers great flexibility of use. It has the
ability to gather information from a broad spectrum of sampling: in the field, in satellite
facilities, in clinics, and in large volume central laboratories. It requires no skilled labor.
Because it is a stable powder, it can be inexpensively transported. Its cost is 20% of genetic
amplification and 75% of conventional processing surveillance samples.
2.1.4. Additional S. aureus screen: EPI-VISA®
The screen for vancomycin-intermediate resistant S. aureus (VISA) utilizes the EPI-M® base
with the substitution of 3 mcg/mL (3 mg/L) of vancomycin for cefoxitin. The colors produced
are the same as the EPI-M®.
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2.2. Screening Method for Vancomycin-resistant Enterococci (VRE)
Both asymptomatically colonized and infected patients serve as reservoirs for transmission of
VRE, as well as contaminated surfaces and patient care equipment. European Union and
United States public health agencies have developed recommendations for preventing the
transmission of vancomycin resistance within and among hospitals and nursing homes.
Current surveillance methods require a number of sequential steps and needs a special series
of culture media and identification tests. A highly skilled and trained medical technologist is
needed to perform the analysis. Molecular tests are expensive and require special equipment.
A new, simple, and one-step screening method for the detection of VRE (as defined as a
minimum inhibitory concentration (MIC) to vancomycin of 6 mcg/mL) directly from rectal/
perirectal specimens was compared to the Food and Drug Administration (FDA) reference or
predicate method. The screening tool (EPI-V®, Pilots Point LLC, Sarasota, FL) contains all the
required ingredients in a stable powder form, in a standard test tube. The presence of VRE in
a rectal swab is denoted by the production of a two sequential biochemical reactions inside the
test tube: substrate hydrolysis representing bile-esculin followed by pyrrolidonyl arylamidase
(PYR) substrate hydrolysis. Bile-esculin plus PYR is the generally accepted identification of
the genus Enterococcus [13].
2.2.1. Standard culture method
The FDA predicate VRE culture method is Bile Esculin Azide agar with 6 mcg/mL vancomycin
(BEAV) (Remel, Lenexa, KS) [14]. Specimens consisted of 400 sequential human rectal/
perirectal surveillance swabs obtained as part of the ongoing surveillance program. The
collection device was a Culturette™ II (Becton Dickinson and Company, Cockeysville, MD).
There was no prior notification of individuals collecting the specimens. The Culturette™ II
swab was twirled vigorously in 1 mL of pH 7.0, 50 mM HEPES (Sigma-Aldrich, St. Louis, MO)
buffer so that each of the two methods would be challenged with the same inoculum. From
the HEPES buffer, 0.1 mL of the extracted patient specimen was plated on the surface of the
BEAV agar plate. After incubation for 24 hours at 35°C in ambient air, colonies that were brown-
black were gram-stained. Colonies showing gram-positive cocci in chains were then tested by
the PYR reaction (Becton-Dickinson, Cockeysville, MD). The MIC to vancomycin from PYR
positive colonies was performed by the Etest® method (bioMérieux, Durham, NC).
2.2.2. EPI-V®
The EPI-V® screening tool is in a powder format, in a flange-capped test tube, and stored at
room temperature. To use, 3 mL of sterile water was added to dissolve the powder. To this
solution, 0.1 mL of the extracted patient's specimen was added. EPI-V® test tubes were
incubated for a maximum of 24 hours at 35°C in ambient air to call a specimen negative.
However, color development at any time, denoted a positive result. Test tubes demonstrating
a brown-black color (bile-esculin positive) were tilted to coat the disk present in the EPI-V®
cap. This cap contains an enhanced reagent for the detection of PYR hydrolysis [15]. The
Topics in Public Health152
development of a bright fuchsia color within 15 seconds is a positive reaction for PYR. Positive
bile-esculin and PYR results demonstrated the presence of VRE.
In order to determine if a false-positive or false-negative reaction had occurred from the EPI-
V®, approximately 0.1 mL was subcultured from all tests tubes to the surface of a Bile Esculin
Azide agar plate containing 6 mcg/mL vancomycin. Plates were incubated at 35°C for 24 hours
in ambient air. All colonies compatible with Enterococcus were then identified to species. If an
Enterococcus species was isolated, an Etest® MIC to vancomycin was performed. All isolates
were identified to species using the Vitek 2 system (bioMérieux, Durham, NC).
 
 
Figure 5. VRE Negative – Straw-colored with white disk 
Figure 5. VRE Negative – Straw-colored with white disk
 
 
gure 6. VRE Positive – Dark brown/black with bright fuchsia disk 
Figure 6. VRE Positive – Dark brown/black with bright fuchsia disk
The EPI-V® tool, from a diluted specimen, demonstrated a sensitivity of 107% and a specificity
of 98.4%. Table 5 presents the comparison of the EPI-V® results versus the Bile Esculin Azide
(BEAV) culture method. Table 6 presents the time course of the 120 positive analyses by the
EPI-V® tool.
A New Direct Detection System for Antibiotic Resistant Bacteria
http://dx.doi.org/10.5772/59345
153
BEAV Positive BEAV Negative
EPI-V® Positive 111 9
EPI-V® Negative 0 280
Table 5. Comparison of EPI-V® and Bile Esculin Azide Media for the recovery of VRE from stool samples
Time Number of Specimens Positive Cumulative
5 h 12 12
6 h 6 18
7 h 5 23
8 h 11 34
9 h 3 37
10 h 7 44
16 h 73 107
18 h 8 115
20 h 5 120
Table 6. EPI-V® Time to Positive from 120 positive stool samples
The EPI-V® screening tool consists of both a substrate in the liquid (a bile-esculin substrate)
and a detection disk for a second biochemical reaction (PYR).
The EPI-V® tool showed excellent sensitivity and specificity relative to the Bile Esculin Azide
FDA referenced method and required only a maximum of 20 hours. In addition, the EPI-V®
tool offered several significant advantages over the FDA referenced method. These included:
no skilled technologist time required, simple quality control, highly conserved incubator and
refrigerator space, and approximately 1/4-1/3 the cost of agar-based methods. The simplicity
and ease of use of the EPI-V® epidemiology screen allows for more efficient and timely
processing of large numbers of patient surveillance specimens for VRE. This new screen offers
the clinical microbiologist, hospital epidemiologist, or infection control practitioner, flexibility
as to the timing of collection and number of rectal or perirectal patient surveillance cultures.
2.3. Screening Methods for Antibiotic Resistant Enterobacteriaceae
Carbapenems are a class of antibiotics made by modifying penicillin. This chemical modifica‐
tion keeps part of the penicillin molecule, called the beta-lactam structure, and makes the rest
artificial. Therefore, carbapenems are referred to, with other classes of penicillin modified
antibiotics, as semi-synthetic penicillins. The modifications were made because bacteria
rapidly became resistant to penicillin. Chemists added bits and pieces of chemical structures
to penicillin to avoid this resistance. The bacteria figured out how to make enzymes to
chemically destroy these new modifications. After 70+ years of this war between chemists and
bacteria, the bacteria have topped the chemists by making a class of enzymes called carbape‐
nemases [16].
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The original carbapenem was first used in the U.S. in 1976. Since then better forms of this class
have been made chemically. Currently, the most common carbapenem antibiotic used is
meropenem. In the fight between chemists and bacteria, meropenem is the last antibiotic
standing. If a bacterium is resistant to meropenem, there are no good alternatives [16].
2.3.1. What is CRE?
The clinical microbiology laboratory, where infections are diagnosed, divides bacteria into
various shapes (spheres are cocci, cylinders are rods) and armor (gram-positive or gram-
negative). A particular class of antibiotic generally has activity against either gram-negative
or gram-positive bacteria, but not both. Carbapenems were developed to treat the gram-
negative bacteria found in hospitals. Gram-negative bacteria in hospitals are associated with
a very large morbidity and mortality, plus tremendous cost.
The gram-negative bacteria that have become resistant to carbapenems are known as CRE, or
carbapenem-resistant enterics. Until a short time ago carbapenem resistance was only in one
type of enteric, called Klebsiella pneumoniae (K. pneumoniae); therefore resistant bacteria were
called K. pneumoniae carbapenemase (KPC). Unfortunately resistance has spread to bacteria
related to Klebsiella and we now use the term CRE. These enteric bacteria normally live in the
intestines of humans [16].
2.3.2. What is the CRE problem?
CRE is primarily a nosocomial associated problem. The likely reasons include the following:
the use of large amounts of various antibiotics that select for the CRE bacteria; the transport
from patient to patient of CRE on the hands of health care workers, including doctors and
nurses; an environment such as a hospital room in which the bacteria can be deposited to infect
new residents. For example, the CRE bacteria can remain alive in hospital rooms for a very
long time period. In one study, after 30 days significant numbers of CRE could be found in a
hospital room, and even after 100 days CRE were recovered. Death rates of up to 50% can be
seen in patients with CRE isolated from the blood. The CDC has identified CRE as one of the
prime problems for hospitalized patients [16].
2.3.3. Impediments to the control of CRE
Lack of funding: There is no billing code for CRE under Medicare and Medicaid. Therefore,
reimbursement for the actual laboratory testing is not available. While there would be a huge
financial benefit to the prevention of infections (in addition to the obvious benefit to the patient)
hospitals do not balance costs and benefits between departments.
Lack of a systems approach: Many hospitals are now actually networks of hospitals. It has been
difficult to achieve uniformity of action across the networks.
Lack of a diagnostic test: The IDSA says “New, rapid accurate diagnostic tests are sorely needed.
Unfortunately, there is little impetus for companies…”
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Need for highly skilled labor: Current methods require several days and utilize highly skilled and
costly labor [16].
2.3.4. Methods for the detection of Carbapenemase-producing Enterobacteriaceae
2.3.4.1. Centers for Disease Control Method
The CDC method utilizes a series of sequential steps and can require up to 4 days to determine
either positive of negative [17].
Procedure:
Step 1. Day One
1. Aseptically, place one 10-μg ertapenem or meropenem disc in 5 mL trypticase soy broth
(TSB).
2. Immediately inoculate the broth with the rectal culture swab.
3. Incubate overnight at 35 ± 2°C, ambient air.
Step 2. Day Two
1. Vortex and subculture 100 μl of the incubated broth culture onto a MacConkey agar plate.
2. Streak for isolation.
3. Incubate overnight at 35 ± 2°C, ambient air.
Step 3. Day Three
1. Examine the MacConkey agar for lactose-fermenting (pink-red) colonies.
2. More than one colony morphology may represent different species of Enterobacteriaceae.
NOTE: Carbapenemases are known to exist in several different species of gram-negative bacilli
including species of Enterobacteriaceae and Pseudomonas aeruginosa (P. aeruginosa). However,
carbapenemases are more common in lactose-fermenting species of Enterobacteriaceae (e.g.
K. pneumoniae and E. coli) than in non-lactose fermenting Enterobacteriaceae (e.g. Serratia
marcescens and some Enterobacter spp.) and P. aeruginosa. In this procedure, it is suggested
that laboratories focus their efforts on detection of resistant lactose-fermenting bacteria to
reduce workload. Healthcare facilities that have identified clinical infections with carbapene‐
mase-producing non-lactose fermenting gram-negative species should consider altering this
procedure to include characterization of colonies with a morphology that is consistent with
those species.
It may be necessary to subculture representative colonies of each morphology type to a non-
selective media for isolation and/or for susceptibility testing. Screen representative isolated
colonies using a phenotypic test for carbapenemase production, such as the Modified Hodge
Test (MHT) or test for carbapenem susceptibility using a standardized method and follow the
CLSI guidelines for identification of carbapenemase-producing Enterobacteriaceae [12].
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Step 4. Day Four
1. For CRE and/or MHT-positive isolates, perform species-level identification.
2.3.4.2. Hydrolysis of Carbapenem Methods
Rapid Detection of Carbapenemase-producing Enterobacteriaceae
This method takes advantages of the observation that the hydrolysis of imipenem results in
an acid molecule. Therefore, the authors incorporate a pH indicator that changes from red to
yellow when acid is produced in sufficient amounts. One advantage of the method is that by
using a pH change, a broad spectrum of carbapenemases can be detected. A significant
disadvantage is that imipenem is not stable and the whole formula must be made fresh each
time it is used. This aspect seriously inhibits the method’s use [18].
Detection of Carbapenemase Producers in Enterobacteriaceae by Use of a Novel Screening Medium
Different concentrations of several carbapenem molecules were tested, and finally, ertapenem
was added to Drigalski agar medium at a concentration of 0.25 mg/mL. ZnSO4 (70 mg/mL)
was added to improve expression of metallo-beta-lactamases (MBLs) by MBL producers.
Cloxacillin (250 mg/mL), which is a cephalosporinase (AmpC-type beta-lactamase) inhibitor,
was used to prevent growth of isolates expressing high levels of cephalosporinases, such as
Enterobacter cloacae (E. cloacae), Enterobacter aerogenes (E. aerogenes), Morganella morgannii (M.
morgannii), and Serratia marcescens (S. marcescens). These isolates are clinically significant
sources of carbapenem resistance associated with an outer membrane permeability defect [19].
2.4. Screening Method for Carbapenem-resistant Enterobacteriaceae (CRE)
EPI-CRE® is a selective and differential medium containing 2 mcg/mL of meropenem, intended
for use in the qualitative detection of gastrointestinal colonization with carbapenem-resistant
Enterobacteriaceae (CRE) to provide epidemiological data. It is based on classical biochemicals
in an optimized form. EPI-CRE® is performed with rectal swabs and fecal specimens from
patients to screen for CRE colonization. The presence of CRE is established when the color of
the medium changes from red to yellow. In addition, a violet precipitate may also be observed.
Specimens should be collected, handled and disposed of in compliance with accepted guide‐
lines and in accordance with all regulations. Cotton swabs should be avoided with preference
to synthetic fibers such as Dacron or rayon. A generally available reference is the Manual of
Clinical Microbiology [8]. EPI-CRE® is performed with rectal swabs and fecal specimens which
should be collected and handled following recommended guidelines [13].
2.4.1. EPI-CRE®
2.4.1.1. Procedure
1. Inoculate the sample into the medium. If a swab is used, twirl the swab in the medium
for 10 seconds and express excess fluid from the swab before removing and discarding
into disinfectant. Do not use a cotton swab.
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2. Incubate the tube(s) at 34-36°C.
3. The tube(s) may be examined any time up to 24 hours for a color change from red to yellow.
If the medium has not become yellow in 24 hours, it is negative.
4. At any time after the start of incubation, if a yellow color is observed, EPI-CRE® is positive.
In addition, a violet precipitate may be observed.
Figure 7. CRE Negative – Red
 
 
Figure 8. CRE Positive – Yellow with violet precipitate 
Figure 8. CRE Positive – Yellow with violet precipitate
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2.4.1.2. Note on the biology of EPI-CRE®
EPI-CRE® detects ONLY living bacteria. It is 100% specific (based on Bergy’s Manual and the
Manual of Clinical Microbiology).
PCR positive and EPI-CRE®negative: Genetic amplification is not to be used as a “test of cure”.
The reason is that PCR and other genetic amplification methods will detect dead bacteria.
Therefore, if a patient is treated intra-nasally or systemically with an effective antibiotic, the
bacteria may be killed but their genetic material still is present. EPI-CRE® only detects living
bacteria so this situation is not a limitation with this method.
2.5. Screening Method for Ciprofloxacin-resistant (cipR) Bacteria
EPI-FLOX® is a selective medium that allows the differentiation of ciprofloxacin-resistant from
ciprofloxacin-susceptible bacteria. EPI-FLOX® contains 2 mcg/mL of ciprofloxacin, intended
for use in the qualitative detection of ciprofloxacin-resistant (cipR) bacteria to provide
epidemiological data. It is based on classical biochemicals in an optimized form. EPI-FLOX®
is performed with urethral swabs and specimens, or rectal swabs and fecal specimens from
patients to screen for cipR bacterial colonization. The presence of cipR bacteria is established
when the color of the medium changes from red to yellow. In addition, a violet precipitate may
also be observed.
The base formula of the EPI-FLOX® is the same as that of EPI-CRE® with the substitution of
ciprofloxacin for meropenem. Therefore the procedure for use and the color changes are the
same.
2.5.1. Note on the utility of the antibiotic resistant Enterobacteriaceae format
Because the base formula is designed to select for lactose positive Enterobacteriaceae, changes
in the antibiotic can easily produce tailored screens. For example, by decreasing the concen‐
tration of meropenem to 0.25 mcg/mL, an epidemiological screen for OXA-48 can be produced.
3. Instrument: Pilots Point Monitor 60® (PPM 60®)
As described above, each of the DSU® epidemiology screens can be done manually. However,
there are advantages to be able to place the screens in an instrument. Among these are:
Standardization: the instrument will read and interpret the screens in a completely uniform
manner.
Positives reported when detected: the instrument monitors the color change of each screen every
15 minutes. Once the algorithm determines that a significant change has occurred compared
to a control the results are reported at that time. Therefore there is continuous monitoring and
reporting. Another benefit is that response time will be shortened.
Satellite screening: Because results are available from the instrument via Wi-Fi, internet, and
intranet, screening at various locations can be controlled from a central location.
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Epidemiological pattern analysis: Either from a central location or from satellite laboratories, data
can be analyzed to determine if any increase of any of the epidemiological threats from any
location is occurring.
Inexpensive cost: the instrument is designed to minimize cost. As shall be discussed below the
instrument’s function is to produce light and measure a change. Data are transferred to a
computer – either a personal computer (PC) or an information technology (IT) system – for
analysis. This format lowers the cost of the instrument.
Single instrument for all screens: Because of the light source chosen (see below) all of the screens,
regardless of color, can be performed in one instrument. Moreover, wavelengths from 360nm
through the entire visible light can be accurately measured, which allowed both fluorescent
(366nm) and visible light measurements. The ability to use both ultraviolet and visible
wavelengths permits the development of two separate biochemical identification systems. The
separation of two biochemicals can allow for the detection of two separate target microbes (if
each is specific for each microbe) of an enhanced specificity for a single target microbe (if the
two together provide enhance specificity over one alone).
3.1. Principle of the instrument
The choice of the light source is critical to the generation of a functioning inexpensive instru‐
ment. Instead of using laser, fluorescence polarization, light scattering, reflectance spectro‐
photometry that are expensive and functionally limited, an inexpensive instrument that uses
a white light generator that passes through the sample was generated. Absorption of one or
more of the colors allows other to pass through. In addition an overall measure of turbidity,
called luminosity, is also measured. For EPI-M® the coagulase coalescence change enhances
the process.
The principal of the instrument is based on the way the human eye sees color.
There are three primary colors that the cones see, which translate into the full range of colors.
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In the analysis program the light coming out of the sample is broken down as shown below.
The first measure, which is called the “L” value, is essentially luminosity. It determines a scale
from black to white. The second measure is the “a” value, which measures a change from green
to red. The third measure is the “b” value, which measures a change from blue (and effectively
includes as shown below yellow). Any particular reading can be determined exactly on the
graph below by knowing the “L”, “a”, and “b” values. The sensitivity of the analysis program
is enhanced because it can relate the changes of any combination of “L”, “a”, and “b” values.
An example of a typical analysis is shown below for an EPI-M® MRSA analysis with standard
ATCC MRSA 43300. The tube is scanned every 15 minutes and “L”, “a”, and “b” values
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generated (see the spreadsheet below for the individual values). The analysis program then
translates the values into graphical form, which are shown above the spreadsheet. The analysis
program then determines by a combination of “L”, “a”, or “b”, or any combination thereof, if
there is a significant change compared to a control. In this analysis 3 log10 of ATCC 43300 was
detected in 14.5 hours.
3.2. The instrument
The inside of the Pilots Point Monitor 60® is shown below. It is designed to accept the largest
number of screens with the smallest footprint. It is approximately 0.8 meters in diameter. In
the current configuration, 6 instruments can be connected to one PC. In practice the instrument
cannot be opened. The tube (as shown in the opened instrument below) in practice is added
to the instrument by sliding the blue plastic bar below the PPM 60® logo so as to expose only
one slot. The instrument via a barcode on the test tube recognizes the name of the screen and
all the demographics of the patient. The carrousel moves past the light generator with each
shift of position every 15 minutes. There is an incubator in the instrument that can be adjusted
+/-0.2°C.
Below is a diagram of the working aspects of the instrument: 46 is the carrousel block, 28 is the
wall of the carrousel. 50 are the holes in the carrousel into which the tubes are place, 34 is the
white light source, and 32 is the detector which reads the amount and quality of light (“L”,
“a”, and “b”) that is represented by 54.
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Below is the instrument as it would be used.
As the scanning of the tubes progresses, the information is sent to a PC or to a central IT station.
This flexibility allows both large and small laboratories, epidemiologists in the field, research‐
ers studying the prevalence of antibiotic resistant bacteria in animals, people, and even surfaces
to use one system.
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3.3. Enhanced sensitivity of the Defined Substrate Utilization® tools
3.3.1. Agar compared to liquid
Compared to agar-based microbial detection systems, liquid with the same formulas are
always more sensitive, meaning liquid has the ability to detect a smaller number of bacteria
than agar and in shorter period of time [10]. The reasons for this difference are based first on
the fact that on the surface of agar, bacteria must make colonies to be observed. A visible colony
requires a minimum number of bacteria. The surface of agar has a surface tension that inhibits
the spreading of the bacterial colony. By comparison in liquid, the bacteria are free to divide
in three dimensions.
In addition, the nutrients from the agar must enter the colony from only one direction – from
the agar vertically into the colony. Likewise the waste products, which are inhibitory to the
growth of the microbial colony, diffuse in close proximity to the developing colony thus
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inhibiting the colony’s lateral development. The production of a colony can be thought to reach
development when the nutrients below the colony (all that is available to it) combined with
the production of waste products cause the bacteria to stop multiplying and expanding. By
contrast, a bacterium in liquid suffers no such inhibitions. Nutrients, including the metabo‐
lizable substrate, are available from all directions. Therefore, there is no inhibition for the
development of the bacteria. Likewise any waste products diffuse away from the developing
bacteria nidus into the liquid, away from the nidus.
3.3.2. Optical parameters
Microbiological optical systems have over the years moved to a microtiter format. The
microtiter structures are either the classical 96 well microtiter tray, or a variation, or a microtiter
format in a vertical series of cupules, as exemplified by the Vitek 2 system (bioMérieux,
Durham, NC). The decrease in the light path has significant negative effects on both sensitivity
and the time to detection. The reason for this is that the optics of light absorbance is governed
by the Beer-Lambert law. As shall be discussed below, the intensity of light is logarithmically
related to the length of the light path. This means that a decrease in the light path results in a
log decrease in the amount of measurable light that reaches the detector. This relationship was
presented as the linear relationship between absorbance and concentration of an absorbing
species.
The general Beer-Lambert law is usually written as:
A=a (lambda) * b * c
where A is the measured absorbance, a (lambda) is a wavelength-dependent absorptivity
coefficient, b is the path length, and c is the analyte concentration.
When working in concentration units of molarity, the Beer-Lambert law is written as:
A=epsilon * b * c
where epsilon is the wavelength-dependent molar absorptivity coefficient with units of M-1 cm-1
Regarding instruments, measurements are usually made in terms of transmittance (T), which
is defined as:
T=I / I o
where I is the light intensity after it passes through the sample and I o is the initial light intensity.
The relation between A and T is:
A=-log T=-log (I / I o)
and this formula is the one that is generally associated with the Beer-Lambert law.
The PPM 60® instrument uses traditional 1 centimeter (cm) light path test tubes. By comparison,
the light path of the well formatted microtiter trays is 0.1 cm and the light path of the Vitek 2
system even less. Therefore, the differences in the light paths inherently make the PPM 60®
instrument on the order of 100 times more sensitive. In terms of number of bacteria per mL, 6
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log10/mL of bacteria is the lowest limit of detection in a 0.1 cm light path (based on turbidity,
without a chemical signal, such as the release of a chromophore from a hydrolysable substrate
or change in a pH indicator) and in a 1 cm pathway, the limit increases to 8 log10/mL.
Practically, because bacteria in log phase have a generation time of 15-20 minutes, the time to
detection in the PPM 60® instrument is much less than other methods, and significantly less
than the observation of colonies on agar.
3.3.3. Example of data produced by the PPM 60® and analysis of a positive
Below are the results from the PPM 60® from a patient isolate of MRSA from the Mt. Sinai
Hospital, New York City, NY, USA (courtesy of Dr. Camille Hamula). The initial inoculum
was less than that found in the nose at 6.0 x 104 CFU.
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There was a significant change beginning at 9 hours and the positive was called at 11.25 hours.
3.3.4. Quantification of CFU/mL by the PPM 60® instrument
The time to a positive is proportional to the number of bacteria in the sample. Bacteria go
through four stages of growth in liquid (but not agar): lag phase, log phase, stationery phase,
and decline phase.
It is well known that the greater the number of bacteria in a sample, the shorter the lag phase.
Lag phase is the time that the bacteria acclimate to a new environment. When bacteria enter a
new environment, there is a heterogeneous population in terms of physiological health. Each
of the cells acclimates to the new environment and leave lag phase and enter log phase at
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different times. By analogy it is similar to a kettle of popcorn kernels; one adds the kernels and
all are in the same oil at the same temperature. The “healthier” ones pop first, the number of
pops increase, and then there are a very large number of pops. Then there is a declining number
of pops. Likewise with bacteria, some leave lag phase and enter log phase before others. The
greater the number of bacteria, the shorter is the overall time the population goes from lag
phase to log phase. In the PPM 60® instrument as discussed above, once the bacteria enter log
phase they are dividing every 15-20 minutes. Therefore, the more bacteria in a population that
leaves lag phase and enters log phase, the shorter the time to a positive since each bacteria
multiplying produces a signal.
Below are examples of the ability of the PPM 60® to provide quantitative information with a
variety of target bacteria.
3.3.4.1. MRSA
Isolate Positive Result Total CFU
Clinical Isolate 50153 6.25 hrs 24,000
Clinical Isolate 43681 6.0 hrs 14,800
Clinical Isolate 42869 8.5 hrs 10,400
Clinical Isolate 51667 9.0 hrs 4,800
ATCC 43300 9.75 hrs 4,000
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3.3.4.2. VRE
3.3.4.3. CRE
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